Efficacy and safety of new direct antiviral agents in hepatitis C virus–infected patients with diffuse large B-cell non-Hodgkin's lymphoma

Hepatology

Volumn 67, Issue 1, 2018, Pages 48-55

  Persico, Marcello ^a   Aglitti, Andrea ^a   Caruso, Rosa ^a   De Renzo, Amalia ^b   Selleri, Carmine ^a   Califano, Catello ^c   Abenavoli, Ludovico ^d   Federico, Alessandro ^e   Masarone, Mario ^a  

^a UNIVERSITY OF SALERNO   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c Umberto i Hospital   (Italy)

^d UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^e SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; BIOCHEMICAL MARKER; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; LACTATE DEHYDROGENASE; LEDIPASVIR PLUS SOFOSBUVIR; METHOTREXATE; MITOXANTRONE; PREDNISOLONE; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANN ARBOR SCORE; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ASSESSMENT TOOL; CLINICAL EVALUATION; COHORT ANALYSIS; CORRELATION ANALYSIS; DIARRHEA; DIFFUSE LARGE B CELL LYMPHOMA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 1B; HUMAN; INTERNATIONAL PROGNOSTIC INDEX; LEUKOPENIA; LIVER STIFFNESS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NAUSEA; NONHODGKIN LYMPHOMA; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RASH; RETROSPECTIVE STUDY; REVISED EUROPEAN AMERICAN LYMPHOMA CLASSIFICATION; SEPSIS; SIDE EFFECT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; CASE CONTROL STUDY; CHRONIC HEPATITIS C; COMORBIDITY; KAPLAN MEIER METHOD; LIVER FUNCTION TEST; PATHOLOGY; PATIENT SAFETY; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIVIRAL AGENTS; CASE-CONTROL STUDIES; COHORT STUDIES; COMORBIDITY; DISEASE-FREE SURVIVAL; FEMALE; HEPATITIS C, CHRONIC; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER FUNCTION TESTS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PATIENT SAFETY; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 85034631632     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.29364     Document Type: Article

References (42)

1. Agnello V, De Rosa FG. Extrahepatic disease manifestations of HCV infection: some current issues. J Hepatol 2004;40:341-352.
2. Zignego AL, Ramos-Casals M, Ferri C, Saadoun D, Arcaini L, Roccatello D, et al. International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement. Autoimmun Rev 2017;16:523-541.
3. Musto P. Hepatitis C virus infection and B-cell non-Hodgkin's lymphomas: more than a simple association. Clin Lymphoma 2002;3:150-160.
4. Morgensztern D, Rosado M, Silva O, Santos E, Abdullah S, Goodman M, et al. Prevalence of hepatitis C infection in patients with non-Hodgkin's lymphoma in South Florida and review of the literature. Leuk Lymphoma 2004;45:2459-2464.
5. Nieters A, Kallinowski B, Brennan P, Ott M, Maynadie M, Benavente Y, et al. Hepatitis C and risk of lymphoma: results of the European multicenter case-control study EPILYMPH. Gastroenterology 2006;131:1879-1886.
6. De Vita S, De Re V, Sansonno D, Gloghini A, Gasparotto D, Libra M, et al. Lack of HCV infection in malignant cells refutes the hypothesis of a direct transforming action of the virus in the pathogenesis of HCV-associated B-cell NHLs. Tumori 2002;88:400-406.
7. Zuckerman E, Zuckerman T, Levine AM, Douer D, Gutekunst K, Mizokami M, et al. Hepatitis C virus infection in patients with B-cell non-Hodgkin lymphoma. Ann Intern Med 1997;127:423-428.
8. de Sanjose S, Benavente Y, Vajdic CM, Engels EA, Morton LM, Bracci PM, et al. Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. Clin Gastroenterol Hepatol 2008;6:451-458.
9. Persico M, Capasso M, Persico E, Masarone M, Renzo A, Spano D, et al. Interleukin-10-1082 GG polymorphism influences the occurrence and the clinical characteristics of hepatitis C virus infection. J Hepatol 2006;45:779-785.
10. Negri E, Little D, Boiocchi M, La Vecchia C, Franceschi S. B-cell non-Hodgkin's lymphoma and hepatitis C virus infection: a systematic review. Int J Cancer 2004;111:1-8.
11. Hausfater P, Cacoub P, Sterkers Y, Thibault V, Amoura Z, Nguyen L, et al. Hepatitis C virus infection and lymphoproliferative diseases: prospective study on 1,576 patients in France. Am J Hematol 2001;67:168-171.
12. Zignego AL, Ferri C, Pileri SA, Caini P, Bianchi FB, Italian Association of the Study of Liver Commission on Extrahepatic Manifestations of HCVi. Extrahepatic manifestations of Hepatitis C Virus infection: a general overview and guidelines for a clinical approach. Dig Liver Dis 2007;39:2-17.
13. Matsuo K, Kusano A, Sugumar A, Nakamura S, Tajima K, Mueller NE. Effect of hepatitis C virus infection on the risk of non-Hodgkin's lymphoma: a meta-analysis of epidemiological studies. Cancer Sci 2004;95:745-752.
14. Gisbert JP, Garcia-Buey L, Pajares JM, Moreno-Otero R. Prevalence of hepatitis C virus infection in B-cell non-Hodgkin's lymphoma: systematic review and meta-analysis. Gastroenterology 2003;125:1723-1732.
15. Kawamura Y, Ikeda K, Arase Y, Yatsuji H, Sezaki H, Hosaka T, et al. Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C. Am J Med 2007;120:1034-1041.
16. Gragnani L, Fognani E, Piluso A, Boldrini B, Urraro T, Fabbrizzi A, et al. Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: a prospective, controlled, open-label, cohort study. Hepatology 2015;61:1145-1153.
17. European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol 2017;66:153-194.
18. Hermine O, Lefrere F, Bronowicki JP, Mariette X, Jondeau K, Eclache-Saudreau V, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002;347:89-94.
19. Vallisa D, Bernuzzi P, Arcaini L, Sacchi S, Callea V, Marasca R, et al. Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: a multicenter Italian experience. J Clin Oncol 2005;23:468-473.
20. Peveling-Oberhag J, Arcaini L, Bankov K, Zeuzem S, Herrmann E. The anti-lymphoma activity of antiviral therapy in HCV-associated B-cell non-Hodgkin lymphomas: a meta-analysis. J Viral Hepat 2016;23:536-544.
21. Arcaini L, Rossi D, Paulli M. Splenic marginal zone lymphoma: from genetics to management. Blood 2016;127:2072-2081.
22. Rossotti R, Travi G, Pazzi A, Baiguera C, Morra E, Puoti M. Rapid clearance of HCV-related splenic marginal zone lymphoma under an interferon-free, NS3/NS4A inhibitor-based treatment. A case report. J Hepatol 2015;62:234-237.
23. Merli M, Frigeni M, Gotti M, Grossi P, Bruno R, Passamonti F, Arcaini L. Direct-acting antivirals during or after immuno-chemotherapy in hepatitis C virus-positive diffuse large B-cell lymphomas. Hepatology 2017 Apr 5. doi: 10.1002/hep.29198. [Epub ahead of print]
24. AISF. Indication document of the Italian association for the study of the liver for the rational use of second generation direct antivirals agents in the categories of chronic hepatitis C accepted for reimbursement in italy. 2017. Available at: http://www.webaisf.org/media/38212/documento_hcv_13feb.2017.pdf. Accessed on: May, 5 2017.
25. Economides MP, Mahale P, Kyvernitakis A, Turturro F, Kantarjian H, Naing A, et al. Concomitant use of direct-acting antivirals and chemotherapy in hepatitis C virus-infected patients with cancer. Aliment Pharmacol Ther 2016;44:1235-1241.
26. Kyvernitakis A, Mahale P, Popat UR, Jiang Y, Hosry J, Champlin RE, Torres HA. Hepatitis C virus infection in patients undergoing hematopoietic cell transplantation in the era of direct-acting antiviral agents. Biol Blood Marrow Transplant 2016;22:717-722.
27. Carrier P, Jaccard A, Jacques J, Tabouret T, Debette-Gratien M, Abraham J, et al. HCV-associated B-cell non-Hodgkin lymphomas and new direct antiviral agents. Liver Int 2015;35:2222-2227.
28. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002-1006.
29. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-242.
30. Brice P, Bastion Y, Lepage E, Brousse N, Haioun C, Moreau P, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1997;15:1110-1117.
31. National Institute for Health and Care Excellence. Non-Hodgkin's Lymphoma: Diagnosis and Management. London: National Institute for Health and Care Excellence; 2016.
32. Tilly H, Gomes da Silva M, Vitolo U, Jack A, Meignan M, Lopez-Guillermo A, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015;26(Suppl 5):v116-v125.
33. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361-1392.
34. Cheson BD. What is new in lymphoma? CA Cancer J Clin 2004;54:260-272.
35. International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987-994.
36. Alisi A, Giannini C, Spaziani A, Caini P, Zignego AL, Balsano C. Involvement of PI3K in HCV-related lymphoproliferative disorders. J Cell Physiol 2008;214:396-404.
37. Ishikawa T, Shibuya K, Yasui K, Mitamura K, Ueda S. Expression of hepatitis C virus core protein associated with malignant lymphoma in transgenic mice. Comp Immunol Microbiol Infect Dis 2003;26:115-124.
38. La Mura V, De Renzo A, Perna F, D'Agostino D, Masarone M, Romano M, et al. Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin's lymphoma. J Hepatol 2008;49:557-563.
39. Zignego AL, Ferri C, Giannelli F, Giannini C, Caini P, Monti M, et al. Prevalence of bcl-2 rearrangement in patients with hepatitis C virus-related mixed cryoglobulinemia with or without B-cell lymphomas. Ann Intern Med 2002;137:571-580.
40. Giannelli F, Moscarella S, Giannini C, Caini P, Monti M, Gragnani L, et al. Effect of antiviral treatment in patients with chronic HCV infection and t(14;18) translocation. Blood 2003;102:1196-1201.
41. Visco C, Arcaini L, Brusamolino E, Burcheri S, Ambrosetti A, Merli M, et al. Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy. Ann Oncol 2006;17:1434-1440.
42. Besson C, Canioni D, Lepage E, Pol S, Morel P, Lederlin P, et al. Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programs. J Clin Oncol 2006;24:953-960.